Bioprocessing and fermentation
We specialise in the research, development and production of microorganisms, intermediates, and metabolites using fermentation processes, and apply a broad spectrum of microbiological techniques.
Our MPI-registered facility (PC1/PC2) is fully equipped to take projects from proof of concept through to lab and pilot-scale fermentations of 1000L, which enables pilot-scale demonstration, including for market entry. We are specialists in handling of bacteria, yeasts and fungi, for small molecule and secondary metabolite production, and of genetically modified organisms (GMOs) for biomass. We have applications expertise in biocontrol agents, and in food safe fermentation for food, beverage and health products.
Our areas of expertise
Small molecule and secondary metabolite production optimisation
Large scale production, downstream processing and extraction of secondary metabolites, such as proteins, enzymes, lipids and alkaloids.
Fermentation scale-up and production
A suite of fermentation equipment including 1, 20, 50, 200 and 1000L bioreactors for the growth of bacteria, yeast and fungi. This equipment can be used for multiple applications, including food-grade process development (particularly for beverages), human health products and agritech products such as active horticulture treatments.
Transitional and containment facility for restricted biologics
We manage an MPI-registered containment and transitional facility. This allows us to import biological material (animal or botanical) for extraction and testing, and risk goods such as ‘new to New Zealand’ microorganisms – or transfer such materials from other transitional facilities in New Zealand. We also maintain EPA approvals to allow us to process GMOs and risk goods at up to 1000L scale.
Expand an established company’s probiotic supplements range from the animal market into the human health market.
What we did
BioBrew had a strong reputation in animal nutrition but wanted to enter the human health market. Our biotechnologies team were able to add a layer of technical know-how to BioBrew’s existing knowledge and processing skills, reducing production time and increasing yields. We could also offer BioBrew the right cost model: access to experienced scientists with sophisticated laboratory equipment on a contract basis.
The resulting human product, LiveBrew, has opened up a lucrative new product category for BioBrew, with evidence emerging that probiotics can help with a range of chronic human conditions.